Cover Image

Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review

Despite favorable results of CAR T-cell therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), several challenges remain, including incomplete response, immune-mediated toxicity, and antigen-loss relapse. We delineated the relative clinical benefit of the novel approaches compared to the...

Full description

Saved in:

Bibliographic Details
Main Authors:	Bayarmagnai Weinstein (Author), Bogdan Muresan (Author), Sara Solano (Author), Antonio Vaz de Macedo (Author), YoonJung Lee (Author), Yu-Chen Su (Author), Yeseul Ahn (Author), Gabriela Henriquez (Author), Christina Carmago (Author), Gwang-Jin Kim (Author), David O. Carpenter (Author)
Format:	Book
Published:	University of Minnesota Libraries Publishing, 2021-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma
by: Jain MD, et al.
Published: (2018)

Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin's Lymphoma
by: Maria Giraudo, et al.
Published: (2024)

Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies
by: Hamed Dabiri, et al.
Published: (2023)

Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects
by: Javad Masoumi, et al.
Published: (2021)

Bench‐to‐bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic‐pharmacodynamic model: A case study with anti‐BCMA CAR‐T
by: Aman P. Singh, et al.
Published: (2021)

Chimeric miRNA cluster enables multiplex and titratable gene inhibition in CAR-T cells
by: Reka Agnes Haraszti
Published: (2023)

Chimeric antigen receptor (CAR) T-cell therapy: Harnessing extracellular vesicles for enhanced efficacy
by: Beatrice Spokeviciute, et al.
Published: (2024)

Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing
by: Qibin Liao, et al.
Published: (2020)

The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors
by: Kaveh Hadiloo, et al.
Published: (2023)

Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD)
by: Kathryn Kline, et al.
Published: (2023)

Chimeric antigen receptor-natural killer (CAR-NK) cell immunotherapy: A bibliometric analysis from 2004 to 2023
by: Wangshu Li, et al.
Published: (2024)

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
by: Zakaria Grada, et al.
Published: (2013)

Relevant nursing measures for the adverse reactions associated with chimeric antigen receptor T cells (CAR-T) immunotherapy: a systematic review of case reports†
by: Zhang Xu, et al.
Published: (2019)

Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T‐cellular therapy development
by: Johannes Kast, et al.
Published: (2022)

PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo
by: Qibin Liao, et al.
Published: (2020)

Engineering CAR-T cells
by: Cheng Zhang, et al.
Published: (2017)

Chimeric RNA in Cancer and Stem Cell Differentiation
by: Justin Elfman, et al.
Published: (2018)

Donor T cells for CAR T cell therapy
by: Tiffany C. Y. Tang, et al.
Published: (2022)

Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis
by: James Signorovitch, et al.
Published: (2023)

Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope
by: Alejandrina Hernández-López, et al.
Published: (2021)

Chimeric maternal cells as T lymphocyte targets in pediatric SLE
by: Stevens Anne M, et al.
Published: (2012)

Chimeric antigen receptor T cell therapy for multiple myeloma
by: Kana Hasegawa, et al.
Published: (2019)

Immunogenicity in CAR T cell immunotherapy
by: Emily Yu
Published: (2023)

Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model
by: Aman P. Singh, et al.
Published: (2020)

New advances in leukaemia immunotherapy by the use of Chimeric Artificial Antigen Receptors (CARs): state of the art and perspectives for the near future
by: Cribioli Elisabetta, et al.
Published: (2011)

The FDA's Regulatory Framework for Chimeric Antigen Receptor‐T Cell Therapies
by: Peter Marks
Published: (2019)

Biomarkers in individualized management of chimeric antigen receptor T cell therapy
by: Mengyi Du, et al.
Published: (2020)

Chimeric antigen receptor-T cells immunotherapy for targeting breast cancer
by: Ilnaz Rahimmanesh, et al.
Published: (2021)

The EBMT/EHA CAR-T Cell Handbook
Published: (2022)

The EBMT/EHA CAR-T Cell Handbook
Published: (2022)

The EBMT/EHA CAR-T Cell Handbook
Published: (2022)

General and Specific Cytotoxicity of Chimeric Antisense Oligonucleotides in Bacterial Cells and Human Cell Lines
by: Katya B. Popova, et al.
Published: (2024)

Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
by: Zixun Yin, et al.
Published: (2021)

Unlocking T cell exhaustion: Insights and implications for CAR-T cell therapy
by: Dian Xiong, et al.
Published: (2024)

Model‐informed drug development of autologous CAR‐T cell therapy: Strategies to optimize CAR‐T cell exposure leveraging cell kinetic/dynamic modeling
by: Anna M. Mc Laughlin, et al.
Published: (2023)

Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment
by: Xuejia Kang, et al.
Published: (2024)

Chimeric antigen receptor engineered cells and their clinical application in infectious disease
by: Chen Qian, et al.
Published: (2022)

Quantitative Systems Pharmacology Model of Chimeric Antigen Receptor T‐Cell Therapy
by: Deni Hardiansyah, et al.
Published: (2019)

PSCA is a target of chimeric antigen receptor T cells in gastric cancer
by: Di Wu, et al.
Published: (2020)

Circulating maternal chimeric cells have an impact on the outcome of biliary atresia
by: Ryuta Masuya, et al.
Published: (2022)